Back to top

CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher
April 12, 2018

Read MoreHide Full Article

CymaBay Therapeutics, Inc. (CBAY - Free Report) was a big mover last session, as the company saw its shares rise more than 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $11.10 –$14.00 in the past one-month time frame, witnessed a sharp increase yesterday.

The move came after the company announced positive new 12-week and 26-week results from its ongoing phase 2 study of seladelpar in patients with primary biliary cholangitis.

The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

 

CymaBay Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked stock in the Medical sector is Corium International, Inc. (CORI - Free Report) , which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is CBAY going up? Or down? Predict to see what others think: Up or Down

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


CymaBay Therapeutics Inc. (CBAY) - free report >>

Corium International, Inc. (CORI) - free report >>


More from Zacks Tale of the Tape

You May Like